The 3 C's Of mRNA-LNP Material Sourcing: Commoditization, Customization, & [Supply] Constriction

In response to an audience poll question gauging which cGMP materials have proven the most difficult to source, Gregory Troiano, head of cGMP strategic supply and operations, mRNA Center of Excellence, Sanofi, & April Sena, senior director, technical operations, Life Edit Therapeutics, provide additional clarity around which IVT & LNP-related materials today are more “commoditized” (i.e., accessible), which require additional customization, and which remain the hardest to source.